Radioiodine Refractory Differentiated Thyroid Carcinoma

A key opinion leader discusses the evolving treatment landscape for radioiodine refractory differentiated thyroid carcinoma, with special consideration of the phase 3 SELECT trial.

EP. 1: Phase 3 SELECT Trial Overview

July 13th 2020

EP. 2: SELECT Trial: Toxicity, Duration of Response, and Dose Reduction

July 13th 2020

EP. 3: What is Radioiodine-Refractory DTC?

July 13th 2020

EP. 4: Radioiodine-Refractory DTC: NCCN Guidelines

July 13th 2020

EP. 5: Multikinase Inhibitor Overall Survival Advantage

July 13th 2020

Advertisement

Advertisement